Johannesburg – United States (US) drug developer Novavax said it would begin a mid-stage study of its experimental Covid-19 vaccine in South Africa.
The phase 2B trial study will be conducted on about 2,665 healthy adults and will evaluate the safety and immune system response of about 240 medically stable, HIV positive adults.
Novavax research chief Gregory Glenn said because South Africa was experiencing a winter surge of Covid-19 cases, the trial has the potential to provide an early indication of efficacy.
South Africa is the fifth worst affected country in the world with 583, 000 cases of coronavirus.
Leave a Reply